AVLN — Avalyn Pharma Inc. Common Stock

AVLN closed at $27.14 (+4.22%) on Oct 26, 2026. Float: 20.3M shares. Latest SEC filing: SCHEDULE 13G on Aug 14, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for AVLN in the TickerWise workspace.

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Company profile

• Sector: Healthcare
• Industry: Medical - Pharmaceuticals
• Country: US
• Exchange: NASDAQ
• Employees: 50
• Website: http://www.avalynpharma.com

Latest SEC filings for AVLN

• 2026-08-14SCHEDULE 13G
• 2026-08-1210-Q
• 2026-08-128-K
• 2026-08-06SCHEDULE 13G/A
• 2026-07-018-K
• 2026-06-178-K
• 2026-06-0310-Q
• 2026-06-038-K
• 2026-05-07SCHEDULE 13G
• 2026-05-05SCHEDULE 13G

Related companies

• ONC — BeOne Medicines Ltd.
• LQDA — Liquidia Corporation
• DFTX — Definium Therapeutics, Inc.
• LTGO — Latigo Biotherapeutics Inc.
• LFMDP — LifeMD, Inc.
• CGEM — Cullinan Therapeutics, Inc.
• CUVL — Clinuvel Pharmaceuticals Ltd.
• ETRA — Electra Therapeutics Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.